Skip to main content

Mechanism of Action

References: 1. Advanced Accelerator Applications receives FDA approval for Lutathera® for treatment of gastroenteropancreatic neuroendocrine tumors [news release]. East Hanover, NJ: Novartis Pharmaceuticals Corp; January 26, 2018. Accessed April 15, 2022. 2. Zamora V, Cabanne A, Salanova R, et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis. 2010;42(3):220-225. 3. Lutathera. Prescribing information. Novartis Pharmaceuticals Corp.